Turner J G, Brownlie B E, Sadler W A, Jensen C H
Acta Endocrinol (Copenh). 1976 Sep;83(1):86-92. doi: 10.1530/acta.0.0830086.
The rate of control of thyrotoxicosis during the first 2 weeks of treatment was documented in 63 patients. Twenty-three patients received carbimazole 40 mg plus lithium carbonate 750 mg daily and a comparable group of 20 patients were given carbimazole 40 mg plus potassium iodide 120 mg daily. In the lithium treated patients the mean percentage fall of serum T4 after 2 weeks treatment was 49% and the fall in serum T3 57%. The results were similar in the iodide treated patients; the mean falls in serum T4 and T3 being 47% and 64%, respectively. Serum lithium values varied between 0.1-1.25 mEq./l; lithium side effects were minor. In a companion study 20 patients were treated with carbimazole alone. The responses in this group were less impressive; the mean falls in serum T4 and T3 at 2 weeks being 18% and 36%, respectively. It is concluded that lithium is a safe adjunct to conventional antithyroid drug therapy in the initial treatment of acute thyrotoxicosis.
记录了63例患者在治疗前2周甲状腺毒症的控制率。23例患者每日接受40毫克卡比马唑加750毫克碳酸锂治疗，另一组20例患者每日接受40毫克卡比马唑加120毫克碘化钾治疗。接受锂治疗的患者在治疗2周后血清T4平均下降百分比为49%，血清T3下降57%。碘化钾治疗的患者结果相似；血清T4和T3平均下降分别为47%和64%。血清锂值在0.1 - 1.25毫当量/升之间变化；锂的副作用较小。在一项配套研究中，20例患者仅接受卡比马唑治疗。该组的反应不太明显；2周时血清T4和T3平均下降分别为18%和36%。结论是，在急性甲状腺毒症的初始治疗中，锂是传统抗甲状腺药物治疗的安全辅助药物。
